These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32055804)

  • 21. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.
    Song Y; Lao Y; Liang F; Li J; Jia B; Wang Z; Hui X; Lu Z; Zhou B; Luo W; Song B
    Medicine (Baltimore); 2019 Aug; 98(34):e15415. PubMed ID: 31441835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].
    Calfunao S; Carrasco M; Gutierrez C; Cerpa L; Varela N; Quiñones L
    Rev Med Chil; 2023 Oct; 151(10):1375-1384. PubMed ID: 39093141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
    Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
    Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
    Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
    Front Immunol; 2020; 11():635. PubMed ID: 32322257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    Hussain R; O'Leary S; Pacheco FM; Zacharias TE; Litvak P; Sguigna P; Marder E; Kia K; Kooner K; Stüve O
    J Neurol; 2016 Mar; 263(3):606-10. PubMed ID: 26914924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Cree BA; Magnusson B; Rouyrre N; Fox RJ; Giovannoni G; Vermersch P; Bar-Or A; Gold R; Piani Meier D; Karlsson G; Tomic D; Wolf C; Dahlke F; Kappos L
    Mult Scler; 2021 Sep; 27(10):1564-1576. PubMed ID: 33205682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence.
    Magnusson BP; Schmidli H; Rouyrre N; Scharfstein DO
    Stat Med; 2019 Oct; 38(23):4761-4771. PubMed ID: 31386219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

  • 33. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
    Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
    Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
    Kondo T
    Brain Nerve; 2020 May; 72(5):517-523. PubMed ID: 32381749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
    JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.
    Spampinato SF; Merlo S; Sano Y; Kanda T; Sortino MA
    Biochem Pharmacol; 2021 Apr; 186():114465. PubMed ID: 33577891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
    Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
    J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
    Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
    CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.